Your session is about to expire
← Back to Search
Stereotactic Body Radiation Therapy for Head and Neck Squamous Cell Carcinoma
Study Summary
This trial is testing a new way to treat head and neck squamous cell cancer that has come back by giving a drug that is activated by radiation therapy together with immunotherapy.
- Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What objectives are the researchers striving to reach with this investigation?
"This clinical trial's primary endpoint is to measure the rate of late onset side-effects associated with dose reduction IMRT and IMPT reirradiation after 6 months post radiation therapy. Other secondary objectives include evaluating acute adverse events, overall response per RECIST v1.1 standards, regional PFS estimated by Kaplan-Meier estimates, as well as median times & 95% confidence intervals calculated from these metrics."
In what applications is Hafnium Oxide-containing Nanoparticles NBTXR3 typically employed?
"NBTXR3, a nanoparticle containing hafnium oxide, can be employed to treat malignant neoplasms, inoperable melanoma, and microsatellite instability high."
Can you provide an assessment of the potential harms associated with Hafnium Oxide-containing Nanoparticles NBTXR3?
"Relying on the evidence available in a Phase 2 trial, our team at Power settled on an estimated safety rate of 2 for Hafnium Oxide-containing Nanoparticles NBTXR3. Though there is data that supports its security, efficacy has yet to be proven."
What is the current size of the cohort enrolled in this trial?
"Unfortunately, at the present moment this research is not seeking participants. It was first launched on March 9th 2021 and last updated on May 23rd 2022. Those searching other trials may find 3462 studies recruiting patients with oral squamous cell carcinoma and another 961 for Hafnium Oxide-containing Nanoparticles NBTXR3 actively enrolling volunteers."
Is this study inviting new participants to join?
"As of now, this particular study is not enrolling any additional patients. It was first advertised on March 9th 2021 and the listing was most recently modified on May 23rd 2022. For those looking for alternate trials that might be suitable, there are 3462 clinical studies recruiting participants with oral squamous cell carcinoma and an additional 961 medical investigations actively searching for volunteers to partake in Hafnium Oxide-containing Nanoparticles NBTXR3 trial."
Have any other experiments been conducted to evaluate the efficacy of Hafnium Oxide-containing Nanoparticles NBTXR3?
"At present, there are 961 active clinical trials examining the effects of Hafnium Oxide-containing Nanoparticles NBTXR3 with 122 in Phase 3. Houston, Texas is among many locations running these tests - 35727 to be exact."
Share this study with friends
Copy Link
Messenger